Litcius/Paper detail

Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study

Pier Luigi Zinzani, Koji Izutsu, Neha Mehta–Shah, Stefan K. Barta, Kenji Ishitsuka, Raúl Córdoba, Shigeru Kusumoto, Emmanuel Bachy, Kate Cwynarski, Giuseppe Gritti, Anca Prica, Eric D. Jacobsen, Tatyana Feldman, Yann Guillermin, Daisuke Ennishi, Dok Hyun Yoon, Eva Domingo‐Doménech, Jasmine Zain, Jie Wang, Jin Seok Kim, Marjolein van der Poel, Jin Jin, Sutan Wu, Yang Chen, Takaya Moriyama, Ai Inoue, Keiko Nakajima, Sarah McCue Horwitz

2024The Lancet Oncology49 citationsDOIOpen Access PDF

Topics & Concepts

Open labelRefractory (planetary science)MedicinePeripheralPhases of clinical researchLymphomaPeripheral T-cell lymphomaInternal medicineT cellClinical trialMaterials scienceImmunologyComposite materialImmune systemT-cell and Retrovirus StudiesLymphoma Diagnosis and TreatmentViral-associated cancers and disorders
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study | Litcius